152 related articles for article (PubMed ID: 28482433)
21. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
22. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
23. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
25. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
[TBL] [Abstract][Full Text] [Related]
27. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
28. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract.
Helpap B
Cancer; 2002 Oct; 95(7):1415-20. PubMed ID: 12237909
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
30. Liver metastases in prostate carcinoma: clinical characteristics and outcome.
Pouessel D; Gallet B; Bibeau F; Avancès C; Iborra F; Sénesse P; Culine S
BJU Int; 2007 Apr; 99(4):807-11. PubMed ID: 17155968
[TBL] [Abstract][Full Text] [Related]
31. Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer.
Mori H; Nakajima K; Kadomoto S; Mizokami A; Ikeda H; Wakabayashi H; Kinuya S
Intern Med; 2018 Nov; 57(21):3123-3128. PubMed ID: 29877274
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
33. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
34. Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H; Nakagawa R; Makino T; Kadomoto S; Yaegashi H; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Anticancer Res; 2022 Apr; 42(4):2167-2176. PubMed ID: 35347041
[TBL] [Abstract][Full Text] [Related]
35. Large-cell neuroendocrine carcinoma of prostate. Case report.
Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
[TBL] [Abstract][Full Text] [Related]
37. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
Angulo JC; Redondo C; Sánchez-Chapado M; Colás B; Ropero S; López JI
Pathol Res Pract; 2016 Oct; 212(10):899-903. PubMed ID: 27502465
[TBL] [Abstract][Full Text] [Related]
38. Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
Gan Y; Li Y; Long Z; Lee AR; Xie N; Lovnicki JM; Tang Y; Chen X; Huang J; Dong X
EBioMedicine; 2018 May; 31():267-275. PubMed ID: 29759485
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic characteristics of colorectal neuroendocrine tumor].
Jung SH; Kim HC; Yu CS; Chang HM; Ryu MH; Lee JL; Kim JS; Kim JC
Korean J Gastroenterol; 2006 Aug; 48(2):97-103. PubMed ID: 16929153
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
Hope TA; Aggarwal R; Simko JP; VanBrocklin HF; Ryan CJ
Clin Nucl Med; 2015 Jun; 40(6):540-1. PubMed ID: 25783510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
